Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study

G. K. Rivera, G. Buchanan, J. M. Boyett, B. Camitta, J. Ochs, D. Kalwinsky, M. Amylon, T. J. Vietti, W. M. Crist

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

We devised a plan of intensive chemotherapy to address the problem of inadequate results of treatment in children with acute lymphoblastic leukemia in first bone marrow relapse. Immediately after remission was induced with four conventional drugs, a two-week intensification course of teniposide and cytarabine was given to eradicate subclinical leukemia. Patients in remission were then treated for two years with rapid rotation of pairs of drugs that were not cross-resistant and periodic courses of the same agents used to induce remission. A second complete remission was induced in 31 of the 39 patients in whom response to chemotherapy could be assessed. The probability of maintaining bone marrow remission in these patients for one year was 0.38 ± 0.19 (95 percent confidence interval); the two-year probability was 0.29 ± 0.17. Seven patients completed the treatment program, five of whom have been in continuous second complete remission 17 to 20 months after the cessation of therapy. Children whose initial bone marrow remission lasted less than 18 months had significantly poorer responses to retreatment than did those with a longer first remission (P = 0.004). Intensive chemotherapy, as described here, may save half of the children with acute lymphoblastic leukemia in whom bone marrow relapse occurs after a relatively long initial remission.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalNew England Journal of Medicine
Volume315
Issue number5
StatePublished - 1986

Fingerprint

Retreatment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Pediatrics
Recurrence
Drug Therapy
Teniposide
Cytarabine
Pharmaceutical Preparations
Leukemia
Therapeutics
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rivera, G. K., Buchanan, G., Boyett, J. M., Camitta, B., Ochs, J., Kalwinsky, D., ... Crist, W. M. (1986). Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. New England Journal of Medicine, 315(5), 273-278.

Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. / Rivera, G. K.; Buchanan, G.; Boyett, J. M.; Camitta, B.; Ochs, J.; Kalwinsky, D.; Amylon, M.; Vietti, T. J.; Crist, W. M.

In: New England Journal of Medicine, Vol. 315, No. 5, 1986, p. 273-278.

Research output: Contribution to journalArticle

Rivera, GK, Buchanan, G, Boyett, JM, Camitta, B, Ochs, J, Kalwinsky, D, Amylon, M, Vietti, TJ & Crist, WM 1986, 'Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study', New England Journal of Medicine, vol. 315, no. 5, pp. 273-278.
Rivera, G. K. ; Buchanan, G. ; Boyett, J. M. ; Camitta, B. ; Ochs, J. ; Kalwinsky, D. ; Amylon, M. ; Vietti, T. J. ; Crist, W. M. / Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. In: New England Journal of Medicine. 1986 ; Vol. 315, No. 5. pp. 273-278.
@article{04534db9bad74cdb97137aa78e47f9c5,
title = "Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study",
abstract = "We devised a plan of intensive chemotherapy to address the problem of inadequate results of treatment in children with acute lymphoblastic leukemia in first bone marrow relapse. Immediately after remission was induced with four conventional drugs, a two-week intensification course of teniposide and cytarabine was given to eradicate subclinical leukemia. Patients in remission were then treated for two years with rapid rotation of pairs of drugs that were not cross-resistant and periodic courses of the same agents used to induce remission. A second complete remission was induced in 31 of the 39 patients in whom response to chemotherapy could be assessed. The probability of maintaining bone marrow remission in these patients for one year was 0.38 ± 0.19 (95 percent confidence interval); the two-year probability was 0.29 ± 0.17. Seven patients completed the treatment program, five of whom have been in continuous second complete remission 17 to 20 months after the cessation of therapy. Children whose initial bone marrow remission lasted less than 18 months had significantly poorer responses to retreatment than did those with a longer first remission (P = 0.004). Intensive chemotherapy, as described here, may save half of the children with acute lymphoblastic leukemia in whom bone marrow relapse occurs after a relatively long initial remission.",
author = "Rivera, {G. K.} and G. Buchanan and Boyett, {J. M.} and B. Camitta and J. Ochs and D. Kalwinsky and M. Amylon and Vietti, {T. J.} and Crist, {W. M.}",
year = "1986",
language = "English (US)",
volume = "315",
pages = "273--278",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "5",

}

TY - JOUR

T1 - Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study

AU - Rivera, G. K.

AU - Buchanan, G.

AU - Boyett, J. M.

AU - Camitta, B.

AU - Ochs, J.

AU - Kalwinsky, D.

AU - Amylon, M.

AU - Vietti, T. J.

AU - Crist, W. M.

PY - 1986

Y1 - 1986

N2 - We devised a plan of intensive chemotherapy to address the problem of inadequate results of treatment in children with acute lymphoblastic leukemia in first bone marrow relapse. Immediately after remission was induced with four conventional drugs, a two-week intensification course of teniposide and cytarabine was given to eradicate subclinical leukemia. Patients in remission were then treated for two years with rapid rotation of pairs of drugs that were not cross-resistant and periodic courses of the same agents used to induce remission. A second complete remission was induced in 31 of the 39 patients in whom response to chemotherapy could be assessed. The probability of maintaining bone marrow remission in these patients for one year was 0.38 ± 0.19 (95 percent confidence interval); the two-year probability was 0.29 ± 0.17. Seven patients completed the treatment program, five of whom have been in continuous second complete remission 17 to 20 months after the cessation of therapy. Children whose initial bone marrow remission lasted less than 18 months had significantly poorer responses to retreatment than did those with a longer first remission (P = 0.004). Intensive chemotherapy, as described here, may save half of the children with acute lymphoblastic leukemia in whom bone marrow relapse occurs after a relatively long initial remission.

AB - We devised a plan of intensive chemotherapy to address the problem of inadequate results of treatment in children with acute lymphoblastic leukemia in first bone marrow relapse. Immediately after remission was induced with four conventional drugs, a two-week intensification course of teniposide and cytarabine was given to eradicate subclinical leukemia. Patients in remission were then treated for two years with rapid rotation of pairs of drugs that were not cross-resistant and periodic courses of the same agents used to induce remission. A second complete remission was induced in 31 of the 39 patients in whom response to chemotherapy could be assessed. The probability of maintaining bone marrow remission in these patients for one year was 0.38 ± 0.19 (95 percent confidence interval); the two-year probability was 0.29 ± 0.17. Seven patients completed the treatment program, five of whom have been in continuous second complete remission 17 to 20 months after the cessation of therapy. Children whose initial bone marrow remission lasted less than 18 months had significantly poorer responses to retreatment than did those with a longer first remission (P = 0.004). Intensive chemotherapy, as described here, may save half of the children with acute lymphoblastic leukemia in whom bone marrow relapse occurs after a relatively long initial remission.

UR - http://www.scopus.com/inward/record.url?scp=0022568792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022568792&partnerID=8YFLogxK

M3 - Article

C2 - 3523250

AN - SCOPUS:0022568792

VL - 315

SP - 273

EP - 278

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -